「close」の検索結果

Follow-up scout for the Signals inbox itself. Watches reports that recently transitioned to resolved (an implementation PR merged) and, after a deployment soak window, re-measures the underlying problem to check the fix actually held — plus a strictly-gated escalation check on recently dismissed reports. Emits findings only when a shipped fix demonstrably didn't hold; confirmations and unverifiable verdicts become durable memory and an empty close-out. Self-contained peer in the signals-scout-* fleet — no dependencies on other skills.

日本語の概要は準備中です。原文の説明を表示しています。

Signals scout that watches a PostHog project's most-viewed dashboards and insights for recent anomalies — sudden bursts, drops, flat-lines, and trend breaks at the daily or hourly level. It discovers what the team actually looks at (view counts, dashboard access), curates a durable watchlist in the scratchpad, and balances re-checking known high-value insights (exploit) against discovering new ones (explore) across runs, since no single run can cover a busy project. Anomalies are scored by robust deviation from each insight's own seasonality-matched baseline; it emits a finding only when a move clears the confidence bar, otherwise it updates the baseline memory and closes out empty. Self-contained peer in the signals-scout-* fleet.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and validates quantitative targeted metabolomics assays (MRM/SRM on triple-quadrupole, PRM on high-resolution instruments) to report absolute concentrations. Covers the internal-standard strategy (external cal -> global IS -> standard addition -> stable-isotope-labeled IS), weighted calibration judged by back-calculated %RE not R-squared, ion-ratio quantifier/qualifier confirmation, matrix-effect/recovery characterization, and ICH M10 method validation. Use when quantifying a closed panel of known metabolites with units, building or validating an LC-MS/MS assay, choosing an IS or calibration weighting, or judging whether a reported concentration is trustworthy. For untargeted feature detection see metabolomics/xcms-preprocessing; for group statistics see metabolomics/statistical-analysis; for flux/MID/tracing see metabolomics/isotope-tracing.

日本語の概要は準備中です。原文の説明を表示しています。

Lay out how a job search will actually run alongside a current job: the hours available each week and what they go to, how weekday daytime slots for interviews will be found, which routes to use (direct applications, job boards, scout sites, agents, referrals, public employment services) and what each one discloses to whom, how to keep the search from reaching the current employer through public profiles or workplace equipment, a single tracker of every application's stage, next action, and deadline, and a date and conditions for reviewing, reducing, or pausing the search. Use when someone has decided to start looking, or to gather information while employed, and asks how to fit it in, which routes to use, whether the applications they are running fit the time they have, or how to keep track of them; do not use to decide whether to change jobs, to pick or rate employers or job postings, to predict outcomes, or to send applications, publish profiles, or contact agents on the user's behalf.

日本語の概要は準備中です。原文の説明を表示しています。

Read a Japanese job posting closely and report what it actually states: base pay separated from fixed overtime allowance, the range converted to an hourly basis, required versus preferred requirements, and the terms left ambiguous. Use when a user wants a 求人票 or job description examined before applying, wants two postings compared on the same basis, or wants questions prepared about pay and working conditions; do not use to judge whether the user will be hired, to infer duties the posting does not state, or to evaluate the employer's reputation.

日本語の概要は準備中です。原文の説明を表示しています。

Sort incoming scout messages and agent-forwarded openings by what they actually disclose: whether the employer is named at all, which of pay, location, employment type, and duties are stated, whether the message refers to the applicant's own history or reads as a mass send, whether a stated salary is an offer or a "up to" figure, and whether the same employer has arrived through more than one route. Use when a user has a backlog of scout messages and wants to know which ones can be researched, what to ask before replying, and what to settle before handing over a resume; do not use to rate how promising an opening is, to judge an employer or an agent, or to reply on the user's behalf.

日本語の概要は準備中です。原文の説明を表示しています。

Triage a GitHub issue that already has the cc-issue-created label and is assumed ready to start. Inspect the comment history first to decide whether human confirmation is needed (cc-need-human-check, highest priority — reserved for issue-level deadlock, or for confirmation items answer-issue-questions already investigated and explicitly marked unanswerable); otherwise close the issue as not needed, delegate unanswered confirmation items in the last comment or the description to answer-issue-questions (cc-answer-issue-questions), refresh a description stale relative to settled comment-history content (cc-update-issue), or move to execution (cc-exec-issue). Any UI-changing issue is routed to the design-first flow (cc-create-ui-design) before execution; the exceptions are an issue whose description already names the .pen design to implement against, and a minor UI change that introduces no new visual decision (no new screen/section, no layout change, no new reusable component, no visual expression outside existing design tokens/components). Design files are never edited in the implementation PR. Dependency checks are out of scope.

日本語の概要は準備中です。原文の説明を表示しています。

Create an aggregated Epic PR from a `cc-epic-<Issue number>` branch to the default branch. Takes the Epic Issue number as argument, assumes sub-PRs have already been merged into the epic branch, and automatically generates the PR title and description from the commit log against the base branch (including sub-PR / sub-Issue references). The PR is posted via `gh pr create` with no label and `Closes #<Epic Issue>`.

日本語の概要は準備中です。原文の説明を表示しています。

Handles BED-format genomic intervals (BED3 through BED12, narrowPeak/broadPeak) and the coordinate-system substrate the whole interval category rests on, with bedtools (CLI) and pybedtools/pyranges/pandas (Python). Covers the 0-based half-open vs 1-based-closed convention boundary and the start-1/end-unchanged conversion, the silent failures (chrom-name mismatch, CRLF, lexicographic-vs-version sort under -sorted), genome/chrom.sizes generation, sorting contracts, BED12 block invariants, validation, makewindows, cross-assembly liftover (liftOver/CrossMap), and BED<->VCF/BAM/FASTA conversion. Use when reading, creating, validating, sorting, lifting between genome builds, or converting interval files, preparing inputs for bedtools/tabix/bigBed, or debugging an off-by-one or empty-overlap result.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Transfers gene annotations between genome assemblies via coordinate liftover (UCSC liftOver, CrossMap for same-species version updates) or feature/sequence projection (Liftoff for same/close species, miniprot for protein-level cross-species, TOGA/GeMoMa/CAT for distant clades). Covers the coordinate-vs-projection decision by divergence, why a successful lift is not biological confirmation, reference bias, the silent-dropping of unmapped features, build/PAR/MHC/inversion hazards, and transfer-vs-de-novo validation. Use when annotating a new assembly of a species with an existing reference, harmonizing coordinates across builds, or mapping annotations across related species.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.

日本語の概要は準備中です。原文の説明を表示しています。

Build and analyze pangenomes for prokaryotes (Panaroo, PPanGGOLiN, PEPPAN, GET_HOMOLOGUES, anvi'o pangenomics) and eukaryotes (Minigraph-Cactus, PGGB, vg pangenome graphs). Implement Tettelin core/accessory/cloud genome decomposition (Tettelin 2005), Heap's law open/closed pangenome modeling, gene presence/absence GWAS (Scoary, pyseer), pangenome graph variant calling (vg, PanGenie), and structural-variation graph indexing. Use when assembling species- or genus-level pan-gene catalogs, separating core from accessory/shell/cloud genes, testing gene-content associations with phenotypes, building pangenome graphs from haplotype-resolved assemblies, calling SVs from pangenome graphs, or selecting between bacterial-pangenome and eukaryotic-pangenome workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Build whole-genome alignments using Progressive Cactus (Armstrong 2020 reference-free clade-level WGA), Minigraph-Cactus (Hickey 2024 pangenome-aware), LASTZ chain/net (UCSC pipeline), MUMmer4 (Marçais 2018 pairwise), minimap2 -x asm5/10/20 (Li 2018 fast pairwise), AnchorWave (Song 2022 WGD-aware), and Mauve / progressiveMauve (bacterial). Operates the HAL toolkit (Hickey 2013) for downstream extraction including halSynteny, halLiftover, halBranchMutations, and hal2maf. Use when constructing multi-species alignments for comparative-annotation projection (TOGA), synteny detection, conservation analyses (phyloP / PhastCons), or pangenome graph construction; selecting between reference-free (Cactus) and reference-anchored (LASTZ chains/nets) approaches; tuning sensitivity for closely vs distantly related genomes; or producing HAL files for genome-wide downstream tools.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Route agent work through AccInt's MCP memory loop: retrieve prior outcomes, resolve frames, and close commitments with evidence.

日本語の概要は準備中です。原文の説明を表示しています。

Systematically evaluate weak, stale, or low-conviction theses for upgrade, monitoring, or closure. Use when user says "prune", "kill list", "clean up theses", "what should I close", or "reduce portfolio".

日本語の概要は準備中です。原文の説明を表示しています。

Change conviction level or status on a single thesis. Use when user says "change conviction", "downgrade", "upgrade", "move to monitoring", "close [TICKER]", or "set [TICKER] to [level]".

日本語の概要は準備中です。原文の説明を表示しています。

Conviction-trigger surveillance via Quartr keyword alerts — parse every active thesis's Conviction Triggers for named observables, propose keyword alerts scoped to the Vault Active watchlist (or market-wide for macro observables), create them ONLY on explicit user confirmation, and reconcile the alert set against the book as theses open/close. Use when user says "monitor", "set up alerts", "keyword alerts", "watch for X", or "reconcile alerts".

日本語の概要は準備中です。原文の説明を表示しています。

Estimate calcium-normalized Gapon selectivity coefficients from paired exchange and solution chemistry, or initialize depth-explicit EcoSIM Gapon inputs from the closest bundled ecosystem template when paired chemistry is unavailable. Use when deriving or checking EcoSIM GKC4, GKCH, GKCA, GKCM, GKCN, or GKCK values; matching a target ecosystem, climate, vegetation, and management regime to a starting profile; remapping template values to target soil layers; or documenting that template-based values require calibration or tuning.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user hands over a GitHub issue to be delivered end to end — 'resolver a issue #42', 'loop na issue 42', 'deliver issue https://github.com/o/r/issues/42' — or when an Orca worker preamble dispatches `feat-loop #N`. Turns the issue into a plan, executes it, reviews the result and runs at most 2 fix cycles until APPROVED, then opens a pull request that closes the issue. Never merges. Do NOT use without an issue (feat-feature / feat-quick), to only plan (feat-feature), to only review (feat-review) or to execute an existing plan (feat-exec).

日本語の概要は準備中です。原文の説明を表示しています。